Benzinga · Aug 7, 2026
Guggenheim Maintains Buy on GH Research, Raises Price Target to $40
Guggenheim analyst Eddie Hickman maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $34 to $40.
GH
NASDAQ · GHRS
GH Research PLC
Healthcare · Biotechnology
$27.28
Down-$0.08 (-0.29%)
Updated Sep 11, 2026, 11:30 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 857.25M
- P/E ratio
- -20.9
- Dividend yield
- 0.00%
- 52-week range
- $12.77 – $31.44
- Volume
- 128.8K
- Avg. volume
- 321.53K
Price performance
GHRS price history
1M range · 20 trading sessions · Daily adjusted prices
GHRS closed at $27.28 after 20 trading sessions, down 3.23% for the selected period.
- Last close
- $27.28
- Period change
- -3.23%
- Period low
- $26.98
- Period high
- $29.98
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $27.242 | $27.605 | $26.875 | $27.28 | 128.8K |
| Sep 9, 2026 | $27.77 | $27.92 | $26.46 | $27.56 | 336.85K |
| Sep 8, 2026 | $27.98 | $28.33 | $27.21 | $27.79 | 221.03K |
| Sep 4, 2026 | $27.86 | $28.31 | $27.2618 | $28.23 | 78.1K |
| Sep 3, 2026 | $28.19 | $28.328 | $27.58 | $27.92 | 116.97K |
| Sep 2, 2026 | $27.46 | $28.32 | $27.09 | $28.07 | 111.85K |
| Sep 1, 2026 | $26.94 | $28.00 | $26.6143 | $27.36 | 464.91K |
| Aug 31, 2026 | $27.86 | $28.0698 | $26.68 | $26.98 | 149.18K |
| Aug 28, 2026 | $28.61 | $28.61 | $27.82 | $27.94 | 117.67K |
| Aug 27, 2026 | $29.02 | $29.08 | $28.435 | $28.65 | 73.51K |
| Aug 26, 2026 | $28.92 | $29.1399 | $28.375 | $29.01 | 145.07K |
| Aug 25, 2026 | $28.46 | $29.13 | $28.46 | $28.92 | 113.21K |
| Aug 24, 2026 | $28.20 | $28.60 | $27.2377 | $28.10 | 162.95K |
| Aug 21, 2026 | $28.83 | $29.22 | $28.01 | $28.33 | 141.75K |
| Aug 20, 2026 | $29.74 | $29.8945 | $28.55 | $28.68 | 172.44K |
| Aug 19, 2026 | $29.90 | $30.57 | $29.38 | $29.80 | 357.36K |
| Aug 18, 2026 | $30.00 | $30.26 | $29.045 | $29.735 | 238.66K |
| Aug 17, 2026 | $29.26 | $30.065 | $29.15 | $29.98 | 182.24K |
| Aug 14, 2026 | $28.31 | $30.19 | $28.25 | $29.49 | 233.87K |
| Aug 13, 2026 | $30.31 | $30.31 | $28.0526 | $28.19 | 352.26K |
Latest GHRS news
The latest Smart Investors Daily articles mentioning GHRS.
Stock researchCompany · Overview
GHRS research
Overview
Company profile and research snapshot.
Company profile
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $27.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Buy | — |
| Aug 7, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 6, 2026 | Needham | Buy | — |
| Jul 27, 2026 | Wells Fargo | Overweight | — |
| May 19, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $40
Cantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight and raises the price target from $35 to $40.
Benzinga · Aug 6, 2026
Needham Maintains Buy on GH Research, Raises Price Target to $39
Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $32 to $39.
Benzinga · Aug 6, 2026
GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 53.33 percent decrease over losses of $(0.15) per share from the
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
